SOTERA HEALTH COMPANY Cost of Revenue
SOTERA HEALTH COMPANY (SHC) reported Cost of Revenue of $143.41 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Expense Statement
us-gaap:CostOfRevenue · last filed 2026-08-06
- SOTERA HEALTH COMPANY cost of revenue for the quarter ending 2026-06-30 was $143.41M, a 12.29% increase year-over-year.
- SOTERA HEALTH COMPANY cost of revenue for the quarter ending 2026-03-31 was $132.98M, a 11.66% increase year-over-year.
- SOTERA HEALTH COMPANY cost of revenue for the quarter ending 2025-12-31 was $137.52M, a 9.28% increase year-over-year.
- SOTERA HEALTH COMPANY cost of revenue for the quarter ending 2025-09-30 was $133.75M, a 4.95% increase year-over-year.
- SOTERA HEALTH COMPANY cost of revenue for fiscal 2025 was $518.08M, a 4.00% increase from fiscal 2024.
- SOTERA HEALTH COMPANY cost of revenue for fiscal 2024 was $498.15M, a 5.51% increase from fiscal 2023.
- SOTERA HEALTH COMPANY cost of revenue for fiscal 2023 was $472.13M, a 5.70% increase from fiscal 2022.
- SOTERA HEALTH COMPANY cost of revenue for fiscal 2022 was $446.68M, a 8.21% increase from fiscal 2021.
| Period end | Cost of Revenue 3 month | Cost of Revenue 6 month | Cost of Revenue 9 month | Cost of Revenue 12 month |
|---|---|---|---|---|
| 2026-06-30 | $143.41M 10-Q · filed 2026-08-06 | $276.39M 10-Q · filed 2026-08-06 | $413.91M derived: sum of 3 quarters · filed 2026-08-06 | $547.66M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $132.98M 10-Q · filed 2026-05-05 | $270.50M derived: sum of 2 quarters · filed 2026-05-05 | $404.25M derived: sum of 3 quarters · filed 2026-05-05 | $531.97M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $137.52M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $271.27M derived: sum of 2 quarters · filed 2026-02-24 | $398.99M derived: sum of 3 quarters · filed 2026-08-06 | $518.08M 10-K · filed 2026-02-24 |
| 2025-09-30 | $133.75M 10-Q · filed 2025-11-04 | $261.47M derived: sum of 2 quarters · filed 2026-08-06 | $380.56M 10-Q · filed 2025-11-04 | $506.40M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $127.72M 10-Q · filed 2026-08-06 | $246.81M 10-Q · filed 2026-08-06 | $372.65M derived: sum of 3 quarters · filed 2026-08-06 | $500.09M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $119.09M 10-Q · filed 2026-05-05 | $244.93M derived: sum of 2 quarters · filed 2026-05-05 | $372.37M derived: sum of 3 quarters · filed 2026-05-05 | $496.18M derived: sum of 4 quarters · filed 2026-05-05 |
| 2024-12-31 | $125.84M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $253.28M derived: sum of 2 quarters · filed 2026-02-24 | $377.08M derived: sum of 3 quarters · filed 2026-02-24 | $498.15M 10-K · filed 2026-02-24 |
| 2024-09-30 | $127.44M 10-Q · filed 2025-11-04 | $251.25M derived: sum of 2 quarters · filed 2025-11-04 | $372.31M 10-Q · filed 2025-11-04 | $502.46M derived: sum of 4 quarters · filed 2026-02-24 |
| 2024-06-30 | $123.80M 10-Q · filed 2025-08-08 | $244.86M 10-Q · filed 2025-08-08 | $375.02M derived: sum of 3 quarters · filed 2026-02-24 | $492.21M derived: sum of 4 quarters · filed 2026-02-24 |
| 2024-03-31 | $121.06M 10-Q · filed 2025-05-01 | $251.22M derived: sum of 2 quarters · filed 2026-02-24 | $368.41M derived: sum of 3 quarters · filed 2026-02-24 | $484.10M derived: sum of 4 quarters · filed 2026-02-24 |
| 2023-12-31 | $130.16M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $247.35M derived: sum of 2 quarters · filed 2026-02-24 | $363.04M derived: sum of 3 quarters · filed 2026-02-24 | $472.13M 10-K · filed 2026-02-24 |
| 2023-09-30 | $117.19M 10-Q · filed 2024-11-05 | $232.89M derived: sum of 2 quarters · filed 2024-11-05 | $341.97M 10-Q · filed 2024-11-05 | $451.84M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-06-30 | $115.69M 10-Q · filed 2024-08-05 | $224.78M 10-Q · filed 2024-08-05 | $334.65M derived: sum of 3 quarters · filed 2025-02-27 | $447.34M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-03-31 | $109.09M 10-Q · filed 2024-05-02 | $218.96M derived: sum of 2 quarters · filed 2025-02-27 | $331.65M derived: sum of 3 quarters · filed 2025-02-27 | $447.89M derived: sum of 4 quarters · filed 2025-02-27 |
| 2022-12-31 | $109.87M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $222.56M derived: sum of 2 quarters · filed 2025-02-27 | $338.80M derived: sum of 3 quarters · filed 2025-02-27 | $446.68M 10-K · filed 2025-02-27 |
| 2022-09-30 | $112.69M 10-Q · filed 2023-11-01 | $228.93M derived: sum of 2 quarters · filed 2023-11-01 | $336.81M 10-Q · filed 2023-11-01 | $444.11M derived: sum of 4 quarters · filed 2024-02-27 |
| 2022-06-30 | $116.24M 10-Q · filed 2023-08-03 | $224.12M 10-Q · filed 2023-08-03 | $331.42M derived: sum of 3 quarters · filed 2024-02-27 | $432.00M derived: sum of 4 quarters · filed 2024-02-27 |
| 2022-03-31 | $107.88M 10-Q · filed 2023-05-03 | $215.18M derived: sum of 2 quarters · filed 2024-02-27 | $315.75M derived: sum of 3 quarters · filed 2024-02-27 | $423.91M derived: sum of 4 quarters · filed 2024-02-27 |
| 2021-12-31 | $107.30M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-27 | $207.87M derived: sum of 2 quarters · filed 2024-02-27 | $316.03M derived: sum of 3 quarters · filed 2024-02-27 | $412.81M 10-K · filed 2024-02-27 |
| 2021-09-30 | $100.58M 10-Q · filed 2022-11-02 | $208.73M derived: sum of 2 quarters · filed 2022-11-02 | $305.51M 10-Q · filed 2022-11-02 | $401.78M derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-06-30 | $108.16M 10-Q · filed 2022-08-04 | $204.93M 10-Q · filed 2022-08-04 | $301.20M derived: sum of 3 quarters · filed 2023-02-28 | $393.72M derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-03-31 | $96.78M 10-Q · filed 2022-05-05 | $193.04M derived: sum of 2 quarters · filed 2023-02-28 | $285.56M derived: sum of 3 quarters · filed 2023-02-28 | $379.68M derived: sum of 4 quarters · filed 2023-02-28 |
| 2020-12-31 | $96.27M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | $188.78M derived: sum of 2 quarters · filed 2023-02-28 | $282.90M derived: sum of 3 quarters · filed 2023-02-28 | $374.59M 10-K · filed 2023-02-28 |
| 2020-09-30 | $92.52M 10-Q · filed 2021-11-10 | $186.63M derived: sum of 2 quarters · filed 2021-11-10 | $278.32M 10-Q · filed 2021-11-10 | |
| 2020-06-30 | $94.12M 10-Q · filed 2021-08-12 | $185.80M 10-Q · filed 2021-08-12 | ||
| 2020-03-31 | $91.68M 10-Q · filed 2021-05-13 | |||
| 2019-12-31 | $382.90M 10-K · filed 2022-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Progyny, Inc. (PGNY) | United States | $1.994B | 28.37 |
| agilon health, inc. (AGL) | United States | $1.272B | -7.76 |
| VIEMED HEALTHCARE, INC. (VMD) | United States | $0.336B | 29.92 |
| Park Dental Partners, Inc. (PARK) | United States | $0.094B | |
| BioRestorative Therapies, Inc. (BRTX) | United States | $0.064B | |
| CRYO CELL INTERNATIONAL INC (CCEL) | United States | $0.033B | -11.02 |
| MANGOCEUTICALS, INC. (MGRX) | United States | $0.010B | -0.43 |
| DAVITA INC. (DVA) | United States | $11.147B | 16.80 |